Heartflow, Inc. 2025 Annual Report: Key Highlights and Shareholder Alerts

Overview

Heartflow, Inc. (Nasdaq: HTFL), headquartered in Mountain View, CA, is a leading provider of software and artificial intelligence (AI) solutions designed to deliver more accurate, non-invasive diagnostics and management of coronary artery disease (CAD)—a top cause of death globally. The company’s flagship product, Heartflow FFR_CT Analysis, represented 98% of its total revenue as of December 31, 2025. Heartflow also offers Heartflow Plaque Analysis, an advanced AI-driven tool for rapid, automated 3D coronary plaque assessment, promising optimized medical treatment strategies and efficiency gains for healthcare providers.

Key Points for Investors

• Revenue Concentration: Heartflow FFR_CT Analysis is the company’s main product, accounting for 98% of total revenue. This heavy reliance on a single product is critical for investors to monitor, as any disruption in regulatory approval, reimbursement rates, or competitive threats to FFR_CT could significantly impact financial performance.
• Product Innovation: Heartflow Plaque Analysis leverages AI for automated, precise plaque characterization. The launch and adoption rate of this product will be important to diversify revenue streams and reduce reliance on FFR_CT.
• Nasdaq Listing and Public Float: Heartflow’s common stock began trading on the Nasdaq Global Select Market on August 8, 2025. As of June 30, 2025, there was no established public market for the company’s common stock, making price discovery and liquidity factors to watch closely. As of February 28, 2026, Heartflow had 85,757,754 shares of common stock outstanding.
• Emerging Growth Company Status: Heartflow is classified as an “emerging growth company,” which allows it to take advantage of reduced disclosure requirements and less stringent new accounting standards. Investors should be aware that this status might affect transparency, but also provides Heartflow with more flexibility and reduced compliance costs.
• Internal Controls and Audit Attestation: Heartflow has not filed a report on or attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act. This is typical for emerging growth companies but may increase the risk profile for investors, particularly those concerned about financial controls and audit rigor.
• Forward-Looking Statements: The report makes extensive use of forward-looking statements regarding future operations, product launches, market growth, regulatory climate, and competitive landscape. Investors should note that these statements are subject to substantial uncertainty, and Heartflow explicitly states it cannot guarantee the achievement of these objectives.
• Risk Factors: Heartflow operates in a highly competitive and rapidly changing environment. Risks include reliance on a single product for most revenue, rapid technological evolution, potential regulatory changes, and the need for ongoing innovation. The company advises investors to consult “Risk Factors” in Part I, Item 1A for a comprehensive list.
• Market Value Disclosure: Due to the lack of an established public market prior to August 8, 2025, the aggregate market value of the company’s common stock held by non-affiliates could not be calculated as of June 30, 2025. This may affect valuation and trading dynamics in the initial period post-listing.
• Documents Incorporated by Reference: Portions of Heartflow’s proxy statement for its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report, suggesting forthcoming disclosures on executive compensation, governance, and related party transactions.

Potential Price-Sensitive Factors

• Product Launch and Adoption: The introduction and uptake of Heartflow Plaque Analysis could materially impact future revenues and diversify risk from FFR_CT dependence. Investors should monitor adoption rates and clinical acceptance.
• Nasdaq Listing: The recent listing on Nasdaq opens Heartflow to greater investor scrutiny, liquidity, and potential volatility. Early trading dynamics may be particularly sensitive to news, earnings releases, and regulatory developments.
• Emerging Growth Company Status: While this confers advantages, it also means less rigorous financial controls and fewer disclosures, which may affect investor confidence and share price stability.
• Audit and Internal Controls: Lack of auditor attestation on internal controls could be a concern for institutional investors and may affect share price if any material weaknesses emerge.
• Revenue Concentration Risk: Any negative event affecting FFR_CT—such as reimbursement changes, regulatory issues, or competitive advancements—could significantly impact Heartflow’s top line and share value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information is based on Heartflow, Inc.’s 2025 Annual Report and may contain forward-looking statements subject to risks and uncertainties. Investors should conduct their own due diligence and consult financial professionals before making investment decisions. Heartflow, Inc. undertakes no obligation to update forward-looking statements. Past performance is not indicative of future results.

View Heartflow, Inc. Historical chart here